secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeyondSpring Inc. (BYSI)
CIK:        0001677940
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001171843-25-005355
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Q2 net loss narrows to $1.9M; Plinabulin shows 23% ORR in ICI-refractory cancers
--------------------------------------------------------------------------------

- Net loss from continuing operations $1.9M for Q2 2025 vs $2.7M in Q2 2024; cash $9.5M as of Jun 30, 2025 vs $2.9M Dec 2024.
- R&D expenses $1.0M; G&A $0.9M, down from $1.8M on lower headcount and professional costs.
- Plinabulin combo in PD-1/L1 progressed NSCLC showed median PFS 6.8 mo, ORR 18.2%, DCR 77%, OS 78% at 15 mo.
- SEED Therapeutics' RBM39 degrader ST-01156 cleared FDA IND; Dr. Bill Desmarais appointed CFO and CBO.
- Discontinued operations loss $2.8M vs $1.4M YoY, reflecting SEED reporting change.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1677940/000117184325005355/0001171843-25-005355-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1677940/000117184325005355/f8k_081325.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-005355

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer